Form 4: Bausch + Lomb Director Receives Equity Grant

Director Thomas W. Ross Sr. acquired 15,842 restricted share units as part of an annual compensation grant.

Summary

• Director Thomas W. Ross Sr. was granted 15,842 restricted share units (RSUs) on May 26, 2026.
• The grant was issued under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• Following this transaction, the director's total beneficial ownership of common shares increased to 85,233.
• The RSUs are scheduled to vest on the date immediately preceding the next annual meeting of shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized annual incentive grant indicates stable corporate governance practices.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSUs will vest on the date immediately preceding the next annual meeting of shareholders, at which point they will be settled in common shares.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard practice in the pharmaceutical and medical device industry to ensure long-term alignment with corporate performance.

Comparison to Industry Standards

• The use of an Omnibus Incentive Plan for director compensation is consistent with standard corporate governance practices for large-cap healthcare companies.
• The grant size and structure are typical for non-employee director compensation packages in the sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 15,842 RSUs prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, Form 4, Insider Trading, Equity Compensation, Director Ownership